WASHINGTON--(EON: Enhanced Online News)--Cohen Milstein Sellers & Toll PLLC is conducting an investigation to
determine whether ReWalk Robotics Ltd. (“ReWalk Robotics” or the
“Company”) and certain of its officers and directors made false and
misleading statements and/or omissions in violation of Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934 or committed violations
of Sections 11, 12 and 15 of the Securities Act of 1933.

“substantial lack of
progress towards commencement of the 522 PS study required under the 522
Order.”

Class action lawsuits were filed in the U.S. District Courts for the
Northern District of California and the District of Massachusetts by
other law firms on behalf of purchasers of the common stock of ReWalk
Robotics (NASDAQ: RWLK) pursuant or traceable to the Company’s September
12, 2014 initial public offering, in which the Company raised $41.4
million.

ReWalk is a medical device company that designs, develops and markets
wearable robotic exoskeletons for people with spinal cord injuries. The
complaints allege that ReWalk Robotics and certain of its officers and
directors (“Defendants”) caused ReWalk to issue in connection with its
IPO a Registration Statement and Prospectus ("Registration Statement")
that contained materially misleading statements and/or omitted material
information, including failing to disclose that ReWalk was unprepared or
unable to comply with postmarket regulatory requirements set forth by
the United States Food and Drug Administration ("FDA") in order to
maintain ongoing sales of its exoskeleton device.

On or about February 25, 2016, the FDA posted a copy of a warning letter
sent to ReWalk to its website. According to the warning letter, the FDA
ordered ReWalk, on June 26, 2014, to conduct a postmarket surveillance
(“PS”) study of the company’s exoskeleton device in accordance with
section 522 of the Federal Food, Drug and Cosmetic Act. The letter then
recounted more than a year of delays and missed deadlines on ReWalk’s
part leading to the warning letter for ReWalk’s “substantial lack of
progress towards commencement of the 522 PS study required under the 522
Order.” The price of ReWalk shares fell from $11.65 on February 24, 2016
to $10.41 on February 25, 2016.

Cohen Milstein encourages all investors who purchased ReWalk Robotics
common stock pursuant or traceable to the IPO and/or on the open market
between February 27, 2015 and February 25, 2016; or former employees
with information concerning this matter to contact the firm.

If you are a ReWalk shareholder and would like to discuss your right to
recover for your economic loss, you may, without any cost or obligation,
call Cohen Milstein’s Managing Partner, Steven J. Toll at (888) 240-0775
or (202) 408-4600, or email him at stoll@cohenmilstein.com.
If you wish to serve as lead plaintiff, you must move the Northern
District of California Court no later than March 25, 2017, and the
District of Massachusetts Court no later than April 4, 2017, to request
appointment. Any member of the proposed class may retain Cohen Milstein
or other attorneys to serve as your counsel in this action, or you may
do nothing and remain an absent class member.

Cohen Milstein has significant experience in prosecuting investor class
actions and actions involving securities fraud, and is active in major
litigation pending in federal and state courts throughout the nation.
Cohen Milstein has taken a lead role in numerous important cases on
behalf of defrauded investors, and has been responsible for a number of
outstanding recoveries which, in the aggregate, total billions of
dollars. Prior results do not guarantee a similar outcome. For more
information visit www.cohenmilstein.com.

If you have any questions about this notice or the action, or with
regard to your rights, please contact either of the following:

Recent Stories

NEW YORK--(EON: Enhanced Online News)--In a critical victory for investors and traders across the country, a federal judge ruled on July 28 to uphold a majority of claims in a class action lawsuit ... more »

WASHINGTON--(EON: Enhanced Online News)--Einer Elhauge, Petrie Professor of Law at Harvard Law School and Founding Director of the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioeth... more »